See the DrugPatentWatch profile for Eucrisa
What patents cover Eucrisa (crisaborole)?
Eucrisa (crisaborole) is protected by drug-substance, formulation, and method-of-use patent families, plus patent-life extensions that can shift the effective end date of exclusivity and enforcement. The exact set of active, enforceable patents depends on the country and the status of each patent (granted, challenged, expired, or still being litigated).
For a patent-by-patent view (including expiration dates and legal status by jurisdiction), DrugPatentWatch.com is one of the most direct places to check: https://www.drugpatentwatch.com/ --- (search for “Eucrisa” on the site).
When does the Eucrisa patent (or exclusivity) expire?
Patent timelines for Eucrisa are not captured by a single date because multiple patents can govern different claims (for example, the compound vs. specific uses). In practice, challengers and generic applicants focus on the latest blocking patent(s) in a given market and the dates those patents expire or are removed through litigation.
DrugPatentWatch.com tracks those dates in a way that’s easier to verify against the specific patent numbers listed for Eucrisa: https://www.drugpatentwatch.com/
Are companies trying to challenge Eucrisa’s patents?
Patent challenges are typically aimed at enabling earlier generic/therapeutic-competition entry by attacking one or more listed patents (or narrowing their enforceability). Whether Eucrisa has active, public challenges and which patents are being targeted depends on the jurisdiction and docket availability.
To see what’s currently listed as challenged or litigated (and which patents those involve), check DrugPatentWatch.com’s Eucrisa entries: https://www.drugpatentwatch.com/
Can generic crisaborole enter before all Eucrisa patents expire?
Even if one patent expires, others may still block approval or marketing until their expiration dates (or until they’re overturned/allowed to lapse). That’s why “first expiry” does not necessarily mean “launch-ready.”
A practical way to determine the earliest potential entry date is to compare:
- the earliest-expiring Eucrisa patent in a specific market,
- whether a later patent still covers the commercial product or claims,
- and whether any regulatory exclusivity is also in play.
DrugPatentWatch.com helps by listing the patent expiration landscape you would use for that kind of check.
Which competitor products matter if Eucrisa’s protection ends?
Once significant patent protection weakens or expires, the competitive set can shift quickly toward:
- other topical non-steroidal therapies for atopic dermatitis,
- and, where permitted by regulation and patent status, potential generic crisaborole or follow-on formulations.
If you want, tell me the country (US, EU, UK, etc.) and whether you mean “compound patent expiry,” “market exclusivity,” or “earliest possible generic entry,” and I can tailor the patent-date logic to that market.
Source to find the exact Eucrisa patent list and dates
DrugPatentWatch.com (search for Eucrisa): https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com (Eucrisa search)